A recent bill passed in the US House of Representatives proposes a number of changes to malpractice liability rules, including a $250,000 cap on non-economic damages.
Scientists continue to be the targets of legal action from pharmaceutical, medical device, and nutraceutical companies when published studies frame these companies' products in an unfavorable light.
The NP failed to provide standard care.
Knowing when to make a referral and when to look more carefully into a patient's problems on your own is difficult. However, it is important to consider all options when diagnosing a patient.
Under the law, hospitals with EDs must provide for "an appropriate medical screening examination within the capability of the hospital's ED" to determine if an emergency medical condition exists.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Opioid Use Disorder Prevalence at Delivery on the Rise in the US, According to CDC
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Pharmacologically Induced Headache Accompanied by Dilated Cephalic Vessels
- IV Lidocaine May Be Safe, Efficacious for Pediatric Status Migraine
- Gray Matter Changes in Migraine Associated With Clinical Characteristics